EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort

Qi Feng, Pinelopi Manousou iD, Chioma N Izzi-Engbeaya, Rohit Loomba, Mark Thursz, Mark Woodward iD

Liver International · 2026

DOI: 10.1111/liv.70485 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Liver International, 2026. Verfasst von Qi Feng und 5 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health (UK), School of Public Health, Faculty of Medicine, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Fatty Liver, Liver Cirrhosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Biobank, NIHR Imperial Biomedical Research Centre (BRC), NIHR Senior Clinical and Practitioner Research Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims We investigated the associations between SLD, fibrosis stage, and all‐cause and cause‐specific mortality, with a focus on SLD subtypes.

Methods

We analysed 486 156 UK Biobank participants. SLD cases were identified using fatty liver index ≥ 60. Causes of death were confirmed via death registries. Multivariable Cox models estimated associations between SLD, SLD subtypes, FIB4 score and mortality outcomes, including all‐cause mortality, mortality from liver‐related diseases, cardiovascular disease (CVD) and extrahepatic cancers.

Results

SLD was identified in 178 336 participants (36.7%): 73.5% with MASLD, 19.0% with MetALD and 6.4% with ALD. Over a median follow‐up of 13.8 years, 20 766 (11.6%) deaths occurred among people with SLD and 21 754 among those without (307 820; 7.1%), suggesting a higher mortality rate in SLD than in non‐SLD (8.78 vs. 5.25/1000 person‐years). All SLD subtypes were associated with higher all‐cause mortality: MASLD (HR (95% CI): 1.32 (1.29–1.35)), MetALD (1.16 (1.12–1.20)) and ALD (1.36 (1.29–1.44)). Excess mortality was primarily driven by extrahepatic cancer (42.5%) and cardiovascular disease (24.2%), while liver‐related deaths were concentrated among those with ALD and fibrosis. A strong dose–response relationship was observed between FIB4 stratification and mortality, particularly for liver‐related deaths. These associations were independent of socioeconomic status, lifestyle and cardiometabolic risk factors.

Conclusion

SLD is independently associated with increased all‐cause and cause‐specific mortality, with substantial variation across subtypes and fibrosis severity. Extrahepatic cancer and cardiovascular disease are the leading contributors to excess mortality. These findings underscore the need for integrated care strategies targeting metabolic risk, fibrosis progression and cancer prevention in the SLD population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverLiver CirrhosisHumansCause of DeathUK BiobankProspective StudiesMaleFemaleAdultMiddle AgedAgedBody Mass IndexWaist CircumferenceReference ValuesTriglyceridesLiver Function TestsSeverity of Illness IndexUnited KingdomCost of IllnessRisk FactorsRisk AssessmentProportional Hazards Models

Stichwörter der Autor:innen

ALDMASLDMetALDcancerscardiovascular diseasesfibrosismortalitysteatotic liver disease

Substanzen

Triglycerides

Autor:innen und Institutionen

  • The George Institute for Global Health (UK), School of Public Health, Faculty of Medicine, Imperial College London, London, UK.
  • Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
  • Department of Hepatology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
  • Department of Endocrinology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.

ORCID-Profile: Pinelopi Manousou, Mark Woodward

Förderung

  • UK Biobank
  • NIHR Imperial Biomedical Research Centre (BRC)
  • NIHR Senior Clinical and Practitioner Research Award

Zitieren

APA

Feng, Q., Manousou, P., Izzi-Engbeaya, C. N., Loomba, R., Thursz, M., & Woodward, M. (2026). Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort. Liver International. https://doi.org/10.1111/liv.70485

Vancouver

Feng Q, Manousou P, Izzi-Engbeaya CN, Loomba R, Thursz M, Woodward M. Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort. Liver International. 2026. doi:10.1111/liv.70485

BibTeX
@article{Feng2026,
  author = {Feng, Qi and Manousou, Pinelopi and Izzi-Engbeaya, Chioma N and Loomba, Rohit and Thursz, Mark and Woodward, Mark},
  title = {Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70485}
}
Kostenlos starten →